\ Clinical Trials – Phase 1 CAPRA
ASX Linkedin Twitter               


Clinical Trials – Phase 1 CAPRA

Status: Recruiting Patients

A Phase 1b trial entitled CAPRA (CAvatak and PembRolizumab in Advanced Melanoma) to investigate the use of CAVATAK® in combination with pembrolizumab (KeytrudaTM) in patients with advanced melanoma is underway at Rutgers Cancer Institute in New Brunswick, New Jersey.

The trial is designed to evaluate the safety and tolerability of the established dose of intratumoural CAVATAK in combination with pembrolizumab in 30 patients with advanced melanoma for whom pembrolizumab would be considered the standard of care.

Investigators will also assess evidence of anti-cancer activity, including response rates and bio-markers of anti-tumour immunity.

For further information about this trial, please visit the Clinical Trial website at: ClinicalTrials.gov Identifier: NCT02565992

Click here for the latest news on the CAPRA study


Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2018
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).